2011•Hang'gong uihagRequires access

Clinical Study of Combination Treatment of Recurrent Vulvovaginal Candidiasis of 48 Cases

Luo Zhen

Open publisher page 0 citations

Abstract

Objective:To investigate the appropriate and therapy of treating recurrent vulvovaginal candidiasis(RVVC).Methods:Individual consolidated and maintenance therapy duration.Drugs were usded orally and vaginally together to consolidate the therapy.Oral drugs were itroconazole(200 mg,qn for 5days) or fluconazole(0.15 for one time or 0.15 qw after 0.15 q3d for 2 times).Nystatin(400 000 unit qn for 7 days)or Gyno-Daktarin(0.2 qn for 7 days)was vaginally used.Results:①Among 69 cases of RVVC,C.albicans was mostly detected(85.41%);②The effective rate of individual strengthening and solid therapy was 93.75%,the remote cure rate after discontinuing for 3 months,6 months and 12 months was respectively 89.58%,87.5% and 83.34%,respectively.Conclusions:The predominant pathogen in RVVC is C.albicans.The effective measures to cure RVVC are to Oral therapy and vagina therapy.

About this research paper

What this paper is about

Objective:To investigate the appropriate and therapy of treating recurrent vulvovaginal candidiasis(RVVC).Methods:Individual consolidated and maintenance therapy duration.Drugs were usded orally and vaginally together to consolidate the therapy.Oral drugs were itroconazole(200 mg,qn for 5days) or fluconazole(0.15 for one time or 0.15 qw after 0.15 q3d for 2 times).Nystatin(400 000 unit qn for 7 days)or Gyno-Daktarin(0.2 qn for 7 days)was vaginally used.Results:①Among 69 cases of RVVC,C.albicans was mostly detected(85.41%);②The effective rate of individual strengthening and solid therapy was 93.75%,the remote cure rate after discontinuing for 3 months,6 months and 12 months was respectively 89.58%,87.5% and 83.34%,respectively.Conclusions:The predominant pathogen in RVVC is C.albicans.The effective measures to cure RVVC are to Oral therapy and vagina therapy.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To investigate the appropriate and therapy of treating recurrent vulvovaginal candidiasis(RVVC).Methods:Individual consolidated and maintenance therapy duration.Drugs were usded orally and vaginally together to consolidate the therapy.Oral drugs were itroconazole(200 mg,qn for 5days) or fluconazole(0.15 for one time or 0.15 qw after 0.15 q3d for 2 times).Nystatin(400 000 unit qn for 7 days)or Gyno-Daktarin(0.2 qn for 7 days)was vaginally used.Results:①Among 69 cases of RVVC,C.albicans was mostly detected(85.41%);②The effective rate of individual strengthening and solid therapy was 93.75%,the remote cure rate after discontinuing for 3 months,6 months and 12 months was respectively 89.58%,87.5% and 83.34%,respectively.Conclusions:The predominant pathogen in RVVC is C.albicans.The effective measures to cure RVVC are to Oral therapy and vagina therapy.

Key concepts: Medicine, Vulvovaginal Candidiasis, Fluconazole, Nystatin, Cure rate, Candida albicans, Combination therapy, Vagina

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical Study of Combination Treatment of Recurrent Vulvovaginal Candidiasis of 48 Cases — Research Paper | ScholarLens